Vertex (VRTX.NQ) to buy preclinical company for $950m | Evgen Pharma (EVG.L): SFX-01 for autism clinical trial | Tiziana Life Sciences (TILS.L): Positive Phase 2a data (from yesterday)
05 Sep 2019
SP Angel Healthcare Conditions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare Conditions
- Published:
05 Sep 2019 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
4
Vertex (VRTX.NQ) to buy preclinical company for $950m | Evgen Pharma (EVG.L): SFX-01 for autism clinical trial | Tiziana Life Sciences (TILS.L): Positive Phase 2a data (from yesterday)